Core Viewpoint - The company, Fuhong Hanlin (02696), has received approval from the National Medical Products Administration for clinical trials of a combination therapy involving HLX43, HLX07, and Surulitinib for the treatment of advanced solid tumors, which has positively impacted its stock price [1] Group 1: Company Developments - Fuhong Hanlin's stock rose over 4% in early trading, currently up 3.48% at HKD 56.5, with a trading volume of HKD 12.65 million [1] - The company plans to conduct Phase II clinical research for the combination therapy in China once conditions are met [1] Group 2: Product Information - HLX43 is a novel DNA topoisomerase I inhibitor conjugated with a self-developed PD-L1 targeting antibody, aimed at treating advanced/metastatic solid tumors [1] - HLX07 is an innovative biopharmaceutical developed by Fuhong Hanlin targeting the EGFR, also intended for advanced solid tumor treatment [1] - Surulitinib is an innovative anti-PD-1 monoclonal antibody developed by Fuhong Hanlin [1]
复宏汉霖早盘涨超4% HLX43联合疗法获国家药监局批准开展临床试验